Merck Animal Health Gets European Medicines Agency's Positive CVMP Opinion For An Injectable Formulation Of BRAVECTO (Fluralaner) For Use In Dogs
Portfolio Pulse from Benzinga Newsdesk
Merck Animal Health, a division of Merck & Co., received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Veterinary Use (CVMP) for an injectable formulation of BRAVECTO (Fluralaner) for dogs. The CVMP recommends approval for the treatment of fleas and ticks in dogs for 12 months. The recommendation is pending adoption by the European Commission, which would allow the product to be used by veterinarians for dogs and puppies six months and older.
December 11, 2023 | 11:47 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck & Co.'s Animal Health division received a positive CVMP opinion for its BRAVECTO injectable product for dogs, which could lead to European Commission approval and expanded market opportunities.
The positive opinion from the CVMP is a significant regulatory milestone that can lead to increased sales and market presence in Europe for Merck's Animal Health division. The potential approval by the European Commission would allow the product to be marketed and used across the EU, which is a substantial market. This news is likely to be viewed positively by investors, as it indicates progress in expanding the company's product portfolio and potential revenue streams.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80